Biden’s march-in rights reversal is further evidence of US policy shift on pharma IP rights
US president abandons Trump-era proposal to rule out patent suspensions under the Bayh-Dole Act
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.